Figure 1.
Longitudinal follow-up of PB MRD based on the arm. (A) I arm. (B) I-FCG arm. MRD is expressed as the percentage of evaluable patients, with MRD+ ≥0.01%, low-level positive MRD+ <0.01%, or undetectable MRD subdivided into mutually exclusive (not cumulative) categories depending on the LOD. Undetectable MRD was subdivided as follows: MRD4 for 10-4 ≥ LOD >10-5, MRD5 for 10-5 ≥ LOD >10-6, and MRD6 for LOD ≤10-6. PB MRD was assessed until month 64. N above each bar represents the number of evaluable patients at that time point. ND, not determined.

Longitudinal follow-up of PB MRD based on the arm. (A) I arm. (B) I-FCG arm. MRD is expressed as the percentage of evaluable patients, with MRD+ ≥0.01%, low-level positive MRD+ <0.01%, or undetectable MRD subdivided into mutually exclusive (not cumulative) categories depending on the LOD. Undetectable MRD was subdivided as follows: MRD4 for 10-4 ≥ LOD >10-5, MRD5 for 10-5 ≥ LOD >10-6, and MRD6 for LOD ≤10-6. PB MRD was assessed until month 64. N above each bar represents the number of evaluable patients at that time point. ND, not determined.

Close Modal

or Create an Account

Close Modal
Close Modal